Lisata Therapeutics Partners with Harbour BioMed for Strategic Acquisition of Spruce Biosciences Shares
- Harbour BioMed acquires approximately 3.8% of Spruce Biosciences' common stock, enhancing their strategic partnership.
- The acquisition transitions Harbour BioMed and Spruce from a licensor-licensee model to a collaborative partnership.
- This move strengthens Harbour BioMed's position in biopharmaceuticals, particularly in monoclonal antibody development for innovative therapies.
Harbour BioMed Strengthens Ties with Spruce Biosciences Through Strategic Acquisition
Harbour BioMed announces a significant development in its collaboration with Spruce Biosciences by exercising its warrant to acquire common stock in the company. This transaction enables Harbour BioMed to secure approximately 3.8% of Spruce's total outstanding shares and around 3.1% of its fully diluted shares, based on data from September 30, 2025. This acquisition stems from a collaboration agreement established between Harbour BioMed’s subsidiary, HBM Alpha Therapeutics, and Spruce, which focuses on advancing the development of SPR202, a monoclonal antibody aimed at treating conditions like congenital adrenal hyperplasia. Dr. Jingsong Wang, Harbour BioMed’s Founder, Chairman, and CEO, underscores that this move marks a transition from a traditional licensor-licensee relationship to a more collaborative and strategic partnership, emphasizing the importance of synergy in their shared goal of innovative therapeutic development.
The partnership with Spruce Biosciences is particularly noteworthy given Harbour BioMed's robust capabilities in monoclonal antibody technology. The company's proprietary Harbour Mice® platform is instrumental in producing fully human monoclonal antibodies across various formats, enhancing the potential for effective treatments. Additionally, Harbour BioMed employs cutting-edge technologies, such as HCAb-based immune cell engagers and immune cell antagonists, to create therapies that target immunological and inflammatory diseases more effectively than conventional methods. This strategic acquisition not only strengthens Harbour BioMed's position in the biopharmaceutical landscape but also fosters a collaborative environment that could lead to breakthrough advancements in antibody therapeutics.
Furthermore, Harbour BioMed’s commitment to innovation is evident in its extensive research and development framework, supported by global partnerships designed to enhance its pipeline of transformative therapies. By leveraging its advanced antibody technology and collaborative approaches, the company aims to address unmet medical needs and improve patient outcomes worldwide. This recent acquisition of shares in Spruce Biosciences is a clear indication of Harbour BioMed's strategic intent to solidify its role as a leader in the biopharmaceutical industry, particularly in the fields of immunology and oncology.
In related news, Harbour BioMed continues to explore new avenues for growth and innovation within its therapeutic pipeline. The company’s focus on developing novel therapies positions it as a key player in the biopharmaceutical sector. As Harbour BioMed deepens its collaboration with Spruce, industry experts anticipate that the partnership will yield significant advancements in the treatment of complex medical conditions, ultimately benefiting patients in need of new therapeutic options.
